Matthew Abbott
Neurology · Augusta, GANPI 1417572959
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by UCB, Inc. at 27.8% of the total.
Across 89 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$596
- Imperative Care, Inc$152
- Livanova USA, Inc.$152
- SK Life Science, Inc.$101
- AbbVie$94
- Jazz Pharmaceuticals Inc.$90
- plus $958 from 27 others
What the payments were for
- Food & beverage$2,142100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 25 | $596 |
| Imperative Care, Inc | 1 | $152 |
| Livanova USA, Inc. | 4 | $152 |
| SK Life Science, Inc. | 4 | $101 |
| AbbVie(2 entities) | 5 | $94 |
| Jazz Pharmaceuticals Inc. | 5 | $90 |
| Johnson & Johnson(2 entities) | 3 | $86 |
| Alnylam Pharmaceuticals Inc. | 3 | $76 |
| Neurelis, Inc. | 3 | $75 |
| AstraZeneca(2 entities) | 3 | $71 |
| Greenwich Biosciences, Inc. | 4 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Nevro Corp. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Merz Pharmaceuticals, LLC | 2 | $42 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Sanofi | 2 | $35 |
| EMD Serono, Inc. | 1 | $29 |
| Neuropace, Inc. | 1 | $29 |
| Baxter Healthcare | 1 | $24 |
| Hospira, Inc. | 1 | $23 |
| Qapel Medical Inc | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Stryker | 1 | $21 |
| Argenx US, Inc. | 1 | $19 |
| Zimmer Biomet | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| NS Pharma, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Novocure Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,142 in reported general payments places this provider in the 55th percentile of 506 neurology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 19 | $454 |
| Levetiracetam | 12 | $317 |
Paid to pharmacies, not to this prescriber.
Other neurology in Augusta
- John MorganAugusta$715K
- Alexis ShaeferAugusta$279K
- Kapil SethiAugusta$52K
- Colin McLeodAugusta$49K
- Debra Moore-HillAugusta$48K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.